Sterling Capital Management LLC Has $6.33 Million Stock Holdings in DexCom, Inc. $DXCM

Sterling Capital Management LLC decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 28.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 100,867 shares of the medical device company’s stock after selling 39,813 shares during the quarter. Sterling Capital Management LLC’s holdings in DexCom were worth $6,334,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Reflection Asset Management bought a new position in DexCom in the 4th quarter worth approximately $25,000. CVA Family Office LLC boosted its position in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the period. MCF Advisors LLC bought a new stake in shares of DexCom in the fourth quarter valued at approximately $32,000. ORG Partners LLC grew its stake in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares during the last quarter. Finally, DV Equities LLC acquired a new stake in shares of DexCom in the fourth quarter worth $36,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In related news, insider Kevin R. Sayer sold 26,759 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the sale, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the transaction, the director directly owned 52,852 shares of the company’s stock, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 46,694 shares of company stock worth $3,343,977 in the last ninety days. Company insiders own 0.28% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on DXCM. Piper Sandler reiterated an “overweight” rating and set a $88.00 target price (up from $75.00) on shares of DexCom in a research note on Monday, June 15th. Robert W. Baird set a $80.00 price target on shares of DexCom in a research report on Friday, May 1st. Evercore upgraded shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective on the stock in a report on Tuesday, March 24th. Barclays reaffirmed an “underweight” rating and set a $64.00 price objective (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Finally, BTIG Research reiterated a “buy” rating and issued a $85.00 target price on shares of DexCom in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.88.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $70.14 on Friday. The business has a fifty day simple moving average of $67.65 and a 200 day simple moving average of $68.08. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $27.06 billion, a price-to-earnings ratio of 29.97, a PEG ratio of 1.16 and a beta of 1.45. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the company earned $0.32 earnings per share. The business’s revenue was up 15.0% compared to the same quarter last year. Sell-side analysts expect that DexCom, Inc. will post 2.57 EPS for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.